Hormone therapy initiation depends on disease extent; some agents avoid testosterone flare, allowing ADT without Casodex in certain cases. Active surveillance is increasingly chosen for favorable ...

Prostate cancer is the most common form of cancer among men in England, with cases surging by 25 per cent between 2019 and 2023, according to NHS data. It’s also the second-deadliest form of the ...

Editor's note: second of two parts; read part one here.. In the first part of our series, we described how PSA is used as a screening tool to help detect prostate cancer in men who don't have symptoms ...

The NHS will not be automatically inviting all men above a certain age to check for prostate cancer, unlike the approach for some other cancers. The UK National Screening Committee has suggested that ...

Fear of discomfort and unnecessary treatment often deters patients from prostate cancer screening, despite the benefits of early detection. Prostate cancer can be asymptomatic, making early detection ...

“This study adjusted for testosterone levels, which can influence PSA and outcomes, and still found a significant association. This strengthens the argument that PSA response to neoadjuvant therapy is ...

A single PSA test at midlife may identify men with a low risk of prostate cancer for up to 20 years, supporting longer screening intervals. Men with a low baseline PSA level at midlife have a low risk ...

Prostate cancer is the second-leading cause of cancer death in American men. About 1 in 8 men will be diagnosed with prostate cancer in their lifetime, and the risk varies depending on age and race.

In a population-based cohort study, a single prostate-specific antigen (PSA) measurement in men aged 45-70 years effectively identified individuals with low risk for cancer. Men with PSA levels < 1.00 ...

ROSEVILLE, California — President Joe Biden's recent prostate cancer diagnosis is raising new questions about the disease and the value of screenings for men. Dr. David Yee, director of Urology and ...